BTIG Reiterates Buy Rating on ArriVent BioPharma, Sets $29 Target
BTIG reiterated its Buy rating and $29.00 price target. The target implies 72.7% upside from the October 15 close of $16.79.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.